An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users

Ronald C. Hershow, Noya Galai, Keiji Fukuda, Judith Graber, David Vlahov, Giovanni Rezza, Robert S. Klein, Don Des Jarlais, Chuck Vitek, Rima Khabbaz, Sally Freels, Richard Zuckerman, Patrizio Pezzotti, Jonathan E. Kaplan

Research output: Contribution to journalArticle

Abstract

To determine whether human T-lymphotropic virus (HTLV) type II coinfection affects progression of human immunodeficiency virus type 1 (HIV) infection, longitudinal data on 370 HIV-infected injection drug users (IDUs) with known HIV seroconversion dates from four cohort studies were pooled. HTLV infection was determined by EIA and confirmed and typed by Western blot. Proportional hazards models were used to determine whether HTLV-II infection was associated with AIDS or AIDS-related mortality. Regression analyses were used to compare declines in CD4 cell percents in singly and dually infected persons. Of 370 IDUs, 61 (16%) were HTLV-II-coinfected. During follow-up, 43 (12%) developed and 24 (6%) died of AIDS. HTLV-II coinfection was not associated with progression to AIDS (relative hazard [RH], .82; 95% confidence interval [CI], 0.34-1.94]) or AIDS mortality (RH, 1.69; 95% CI, 0.62-4.60). Rates of decline in CD4 cell percent were similar in singly and dually infected IDUs. These results suggest that HTLV-II does not affect the progression of HIV infection.

Original languageEnglish (US)
Pages (from-to)309-317
Number of pages9
JournalJournal of Infectious Diseases
Volume174
Issue number2
DOIs
StatePublished - Jan 1 1996

Fingerprint

Human T-lymphotropic virus 2
Virus Diseases
Drug Users
Coinfection
Disease Progression
HIV-1
Acquired Immunodeficiency Syndrome
Injections
Confidence Intervals
Mortality
Proportional Hazards Models
Cohort Studies
Western Blotting
Regression Analysis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. / Hershow, Ronald C.; Galai, Noya; Fukuda, Keiji; Graber, Judith; Vlahov, David; Rezza, Giovanni; Klein, Robert S.; Des Jarlais, Don; Vitek, Chuck; Khabbaz, Rima; Freels, Sally; Zuckerman, Richard; Pezzotti, Patrizio; Kaplan, Jonathan E.

In: Journal of Infectious Diseases, Vol. 174, No. 2, 01.01.1996, p. 309-317.

Research output: Contribution to journalArticle

Hershow, RC, Galai, N, Fukuda, K, Graber, J, Vlahov, D, Rezza, G, Klein, RS, Des Jarlais, D, Vitek, C, Khabbaz, R, Freels, S, Zuckerman, R, Pezzotti, P & Kaplan, JE 1996, 'An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users', Journal of Infectious Diseases, vol. 174, no. 2, pp. 309-317. https://doi.org/10.1093/infdis/174.2.309
Hershow, Ronald C. ; Galai, Noya ; Fukuda, Keiji ; Graber, Judith ; Vlahov, David ; Rezza, Giovanni ; Klein, Robert S. ; Des Jarlais, Don ; Vitek, Chuck ; Khabbaz, Rima ; Freels, Sally ; Zuckerman, Richard ; Pezzotti, Patrizio ; Kaplan, Jonathan E. / An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. In: Journal of Infectious Diseases. 1996 ; Vol. 174, No. 2. pp. 309-317.
@article{0ce9507c01cc4f639b2775b660aebb16,
title = "An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users",
abstract = "To determine whether human T-lymphotropic virus (HTLV) type II coinfection affects progression of human immunodeficiency virus type 1 (HIV) infection, longitudinal data on 370 HIV-infected injection drug users (IDUs) with known HIV seroconversion dates from four cohort studies were pooled. HTLV infection was determined by EIA and confirmed and typed by Western blot. Proportional hazards models were used to determine whether HTLV-II infection was associated with AIDS or AIDS-related mortality. Regression analyses were used to compare declines in CD4 cell percents in singly and dually infected persons. Of 370 IDUs, 61 (16{\%}) were HTLV-II-coinfected. During follow-up, 43 (12{\%}) developed and 24 (6{\%}) died of AIDS. HTLV-II coinfection was not associated with progression to AIDS (relative hazard [RH], .82; 95{\%} confidence interval [CI], 0.34-1.94]) or AIDS mortality (RH, 1.69; 95{\%} CI, 0.62-4.60). Rates of decline in CD4 cell percent were similar in singly and dually infected IDUs. These results suggest that HTLV-II does not affect the progression of HIV infection.",
author = "Hershow, {Ronald C.} and Noya Galai and Keiji Fukuda and Judith Graber and David Vlahov and Giovanni Rezza and Klein, {Robert S.} and {Des Jarlais}, Don and Chuck Vitek and Rima Khabbaz and Sally Freels and Richard Zuckerman and Patrizio Pezzotti and Kaplan, {Jonathan E.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1093/infdis/174.2.309",
language = "English (US)",
volume = "174",
pages = "309--317",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users

AU - Hershow, Ronald C.

AU - Galai, Noya

AU - Fukuda, Keiji

AU - Graber, Judith

AU - Vlahov, David

AU - Rezza, Giovanni

AU - Klein, Robert S.

AU - Des Jarlais, Don

AU - Vitek, Chuck

AU - Khabbaz, Rima

AU - Freels, Sally

AU - Zuckerman, Richard

AU - Pezzotti, Patrizio

AU - Kaplan, Jonathan E.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - To determine whether human T-lymphotropic virus (HTLV) type II coinfection affects progression of human immunodeficiency virus type 1 (HIV) infection, longitudinal data on 370 HIV-infected injection drug users (IDUs) with known HIV seroconversion dates from four cohort studies were pooled. HTLV infection was determined by EIA and confirmed and typed by Western blot. Proportional hazards models were used to determine whether HTLV-II infection was associated with AIDS or AIDS-related mortality. Regression analyses were used to compare declines in CD4 cell percents in singly and dually infected persons. Of 370 IDUs, 61 (16%) were HTLV-II-coinfected. During follow-up, 43 (12%) developed and 24 (6%) died of AIDS. HTLV-II coinfection was not associated with progression to AIDS (relative hazard [RH], .82; 95% confidence interval [CI], 0.34-1.94]) or AIDS mortality (RH, 1.69; 95% CI, 0.62-4.60). Rates of decline in CD4 cell percent were similar in singly and dually infected IDUs. These results suggest that HTLV-II does not affect the progression of HIV infection.

AB - To determine whether human T-lymphotropic virus (HTLV) type II coinfection affects progression of human immunodeficiency virus type 1 (HIV) infection, longitudinal data on 370 HIV-infected injection drug users (IDUs) with known HIV seroconversion dates from four cohort studies were pooled. HTLV infection was determined by EIA and confirmed and typed by Western blot. Proportional hazards models were used to determine whether HTLV-II infection was associated with AIDS or AIDS-related mortality. Regression analyses were used to compare declines in CD4 cell percents in singly and dually infected persons. Of 370 IDUs, 61 (16%) were HTLV-II-coinfected. During follow-up, 43 (12%) developed and 24 (6%) died of AIDS. HTLV-II coinfection was not associated with progression to AIDS (relative hazard [RH], .82; 95% confidence interval [CI], 0.34-1.94]) or AIDS mortality (RH, 1.69; 95% CI, 0.62-4.60). Rates of decline in CD4 cell percent were similar in singly and dually infected IDUs. These results suggest that HTLV-II does not affect the progression of HIV infection.

UR - http://www.scopus.com/inward/record.url?scp=19144372121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19144372121&partnerID=8YFLogxK

U2 - 10.1093/infdis/174.2.309

DO - 10.1093/infdis/174.2.309

M3 - Article

VL - 174

SP - 309

EP - 317

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -